Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Schinzari G, Maiorano B, Rossi E, Bianchi A, Chiloiro S,
Keywords: pNET, non-functioning, sporadic, somatostatin analogs, surveillance,
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,
Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,
#3040 Palliative CT Brachytherapy in Hepatic Metastatic NET
Introduction: Hepatic metastases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may induce prognosis relevant complications in an otherwise stable systemic disease after resection of the primary.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jann H
Authors: Feldhaus F, Jann H, Jonczyk M, Boening G, Wieners G,
Keywords: brachytherapy, afterloading, hepatic metastases, local tumor ablation, local tumor control,
Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Merola E
Authors: Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E,
Keywords: Pancreatic NET, Somatostatin Analogs, Grade 2 and 3, Safety, Efficacy,
Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,
Keywords: Neuroendocrine tumours, lanreotide,